Sibeprenlimab demonstrates 'remarkable' performance in treatment of IgA nephropathy

In this video from GlomCon Hawaii, Dana Rizk, MD, discusses the results of a phase 3 clinical trial concerning the safety and efficacy of sibeprenlimab-szsi in the treatment of immunoglobulin A nephropathy. Rizk, professor of medicine in the division of nephrology at the University of Alabama at Birmingham, explained the mechanism behind sibeprenlimab-szsi (Voyxact, Otsuka), a monoclonal